Promising Anti‐Cancer Effects and Mechanisms of Baicalin and Baicalein in the Treatment of Oral Cancer: A Comprehensive Review
Oral Diseases · 2026-09 · 32 (9) · 2641-2659
DOI: 10.1111/odi.70365 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oral Diseases, online erschienen am 30.05.2026. Verfasst von Zahra Karbasi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Erfan Niayesh Hospital, Tehran, Iran. Hauptthemen laut MEDLINE: Flavonoids, Flavanones, Mouth Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 144 Literaturangaben.
Abstract (Originalsprache)
Aim
This review provides a comprehensive summary of the mechanisms of action and pharmacological activities of baicalin and baicalein in the therapy of oral squamous cell carcinoma (OSCC).
Methods
A comprehensive literature search was conducted using multiple electronic databases to find relevant publications.
Results
Baicalin and its aglycone form, baicalein, are two bioflavonoids from Scutellaria baicalensis , which exhibit selective cytotoxicity in OSCC cells by inducing apoptosis through Bax/Bcl‐2 ratio modulation and caspase‐3 activation with negligible toxicity to normal cells. They also suppress metastatic activities by inducing the expression of E‐cadherin and reducing the expression of vimentin, MMP2, MMP9, and EMT. Antiproliferative effects are mediated by cyclin D1 and p53 inhibition, resulting in cell cycle arrest. Baicalin induces ferroptosis through ferritin heavy chain 1 and glutathione peroxidase 4 inhibition, inducing chemosensitivity. Despite their therapeutic promise, challenges such as poor solubility and low bioavailability hinder clinical translation. Innovative drug delivery systems, including nanoencapsulation, offer promising answers to these challenges. Preclinical investigations confirm their good safety profile, with few adverse effects at therapeutic doses.
Conclusions
These findings underscore the potential of baicalin and baicalein as anti‐cancer agents for OSCC. However, further research and clinical trials are necessary to elucidate their mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erfan Niayesh Hospital, Tehran, Iran.
- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
- Student Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Immunology Department, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
ORCID-Profile: Zahra Karbasi, Amirhossein Sahebkar
Zitieren
APA
Karbasi, Z., Arefnezhad, R., Najafi, M., Malaekeh-Nikouei, A., Yaveri, P., Fatemian, H., Rezaei-Tazangi, F., & Sahebkar, A. (2026). Promising Anti‐Cancer Effects and Mechanisms of Baicalin and Baicalein in the Treatment of Oral Cancer: A Comprehensive Review. Oral Diseases, 32(9), 2641-2659. https://doi.org/10.1111/odi.70365
Vancouver
Karbasi Z, Arefnezhad R, Najafi M, Malaekeh-Nikouei A, Yaveri P, Fatemian H, et al. Promising Anti‐Cancer Effects and Mechanisms of Baicalin and Baicalein in the Treatment of Oral Cancer: A Comprehensive Review. Oral Diseases. 2026;32(9):2641-2659. doi:10.1111/odi.70365
BibTeX
@article{Karbasi2026,
author = {Karbasi, Zahra and Arefnezhad, Reza and Najafi, Mahdis and Malaekeh-Nikouei, Amirhossein and Yaveri, Parnian and Fatemian, Hossein and Rezaei-Tazangi, Fatemeh and Sahebkar, Amirhossein},
title = {Promising Anti‐Cancer Effects and Mechanisms of Baicalin and Baicalein in the Treatment of Oral Cancer: A Comprehensive Review},
journal = {Oral Diseases},
year = {2026},
volume = {32},
number = {9},
pages = {2641--2659},
doi = {10.1111/odi.70365}
}
EUVIMED